11 Feb 2022 17:03
Sensyne Health plc
("Sensyne" or the "Company")
Results of General Meeting
Oxford, U.K. 11 February 2022: Sensyne Health plc (LSE:SENS) today announces that at the General Meeting held earlier today all resolutions proposed were duly passed by shareholders.
The full text of the resolutions is set out in Part IV of the Notice of General Meeting in the Circular which was sent to shareholders on 26 January 2022 (the "Circular") and is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Terms used in this announcement shall be as defined in the Circular unless the context requires otherwise.
Voting on the resolutions was conducted by way of a poll and a summary of the votes received is as follows:
Res No. | Votes For | % | Votes Against | % | Votes Total | % of ISC | Votes Withheld* |
1. Authority to issue Warrants | 115,357,952 | 99.98% | 28,664 | 0.02% | 115,386,616 | 70.02 | 36,007 |
2. Disapply pre-emption rights for Warrants | 115,351,779 | 99.97% | 34,837 | 0.03% | 115,386,616 | 70.02 | 36,007 |
3. General authority to allot securities | 115,350,817 | 99.97% | 35,819 | 0.03% | 115,386,636 | 70.02 | 35,987 |
4. General disapplication of pre-emption rights | 102,652,017 | 88.96% | 12,734,619 | 11.04% | 115,386,636 | 70.02 | 35,987 |
*A vote withheld is not a vote in law and means the percentage of votes cast for and against excludes withheld votes.
In accordance with the terms of the Note Purchase Agreement, the Company has today issued the following Conditional Warrants to the Note Purchasers under the Financing:
Gatemore 1,998,352
Lansdowne 3,597,035
Sand Grove 6,294,813
Peel Hunt 799,341
-ENDS-
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Contact details:
Sensyne Health |
| ||
Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
Dr Christopher Golden James Steel
|
| ||
Liberum (Joint Broker) | |||
Phil Walker William Hall | + 44 (0) 20 3100 2000 | ||
Consilium Strategic Communications | |||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
SternIR | |||
Julie Seidel Julie.seidel@sternir.com | +1 (212) 362 1200 | ||